Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 10/20 | 0.37 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253831 | 0.79 | KCNJ1 (0.35) | DYRK1ADYRK2DYRK1BTGFBR1KCNJ1 | |
| SCHEMBL13745167 | 0.79 | TGFBR1 (0.40) | TGFBR1KCNJ1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL4255030 | 0.79 | DYRK1A (0.38) | DYRK1ADYRK2DYRK1BTGFBR1KCNJ1 | |
| SCHEMBL18041741 | 0.75 | TGFBR1 (0.55) | TGFBR1 | |
| SCHEMBL4251800 | 0.74 | PIK3CG (0.57) | DYRK1ADYRK2DYRK1B | |
| SCHEMBL4251796 | 0.74 | PIK3CG (0.57) | DYRK1ADYRK2DYRK1B | |
| SCHEMBL4253251 | 0.72 | CHEK1 (0.50) | — | |
| SCHEMBL18041661 | 0.72 | PIK3CA (0.47) | TGFBR1 | |
| SCHEMBL4251377 | 0.69 | CYP11B2 (0.41) | — | |
| SCHEMBL4253156 | 0.68 | FYN (0.41) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PI4KA, PIP4K2A | DYRK1A 1743/4885DYRK2 1272/4885DYRK1B 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.